证券之星消息，12月1日南向资金增持36.11万股微创医疗（00853.HK）。近5个交易日中，获南向资金 增持的有4天，累计净增持672.27万股。近20个交易日中，获南向资金增持的有11天，累计净增持968.1 万股。截至目前，南向资金持有微创医疗（00853.HK）8.99亿股，占公司已发行普通股的47.01%。 微创医疗科学有限公司是一家主要从事医疗器械的销售、生产、研究及开发（R&D）的投资控股公 司。该公司通过八个分部开展业务。心血管介入业务分部包括植入器械、通路器械等产品。骨科医疗器 械业务分部包括关节重建、脊柱等器械。心律管理（CRM）业务分部包括起搏器、除颤器等器械。大 动脉及外周血管介入业务分部包括"L-REBOA"主动脉阻断球囊等产品。神经介入业务分部包括脑动脉 粥样硬化狭窄、弹簧圈等产品。结构性心脏病业务分部包括经导管主动脉瓣植入术等产品。手术机器人 业务分部从事手术机器人器械的制造及研发。外科医疗器械业务分部从事外科医疗器械的制造及研发。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股 ...

11月28日，2025分析师大会暨第七届新浪财经"金麒麟"最佳分析师颁奖盛典隆重召开。逾300名权威学 者、公私募掌舵人、上市公司董事长、顶级基金经理、首席分析师齐聚上海，共同探讨中国资本市场的 未来机遇。 同时，第七届新浪财经金麒麟菁英分析师评选结果隆重揭晓。第七届新浪财经金麒麟创新药行业"菁英 分析师"荣誉榜第一名被浙商证券研究团队（首席分析师：吴天昊；团队成员：王班、郭双喜、司清 蕊、丁健行、胡隽扬）斩获。 浙商证券王班 吴天昊、司清蕊医疗器械行业2026年策略指出，支付政策优化，看好高值耗材成长性。 专题：2025分析师大会：资本市场"奥斯卡"！机构称A股迎全球资本涌入的大牛市 医用设备：院内招标恢复、"一带一路"出海拉动，业绩恢复可期。2025年前三季度医用设备收入仍同比 有所增长，但利润同比下滑；2026年看好在院内招标恢复及"一带一路"持续布局下的业绩弹性。 家用医疗：成长性有望恢复。2025年前三季度收入利润同比增速恢复，看好出海等带来的成长性恢复； 低值耗材/IVD：看好新品拉动/技术壁垒较高企业。2025年前三季度量价影响下IVD板块收入利润增速 双降。 投资建议： ①集采风险基本出清、新 ...

（原标题：港股午评|恒生指数早盘跌0.24% 广汽集团领涨固态电池） 智通财经APP获悉，港股恒生指数跌0.24%，跌61点，报25884点；恒生科技指数涨0.11%。港股早盘成交755亿港元。 泡泡玛特(09992)再涨超4%，领涨恒生指数蓝筹。六部门发文鼓励潮玩等消费，公司迎来传统销售旺季。 广汽集团(02238)再涨超12%，埃安UT super开启全面交付，全固态电池产线建成。 紫金黄金国际(02259)逆市涨超2%，旗下各矿山产量增加，未来数年将进入增长阶段。 东岳集团(00189)涨4.62%，机构称锂电池强需求有望维持，PVDF涨价有望。 微创医疗(00853)涨5%，小摩增持超9亿港元股份，美银看好手术机器人业务。 拨康视云-B(02592)再涨12.8%，核心产品CBT-009获得日本及欧洲专利。 剑桥科技(06166)再涨超4%，1.6T光模块预计2026年一季度实现大量出货。 黑芝麻智能(02533)、均胜电子(00699)均涨超4% ，双方共建多芯片平台机器人域控产品。 新股海伟股份(09609)首挂上市破发15%，公司为中国第二大的电容器薄膜制造商。 相关ETF 食品饮料ETF (产 ...

Group 1 - MicroPort Medical (0853.HK) saw a rise of over 5%, reaching HKD 11.36, with a total market capitalization of HKD 21.655 billion [1] - According to the Hong Kong Stock Exchange, JPMorgan increased its stake in MicroPort Medical by acquiring 89.0604 million shares at an average price of HKD 10.4413 per share on November 24, totaling approximately HKD 930 million [1] - Bank of America Securities reaffirmed a "Buy" rating for MicroPort Medical, citing attractive risk-reward dynamics and a diversified high-value consumables product portfolio, with surgical robotics expected to be a key growth driver [1] Group 2 - The company is projected to achieve profitability by the first half of 2026, with revenue forecasts for 2026 to 2034 adjusted upward by 0.1% to 1.5% [1] - The target price for MicroPort Medical has been slightly increased from HKD 16.8 to HKD 17 [1]

Group 1 - MicroPort Medical (00853.HK) saw a morning increase of over 4%, currently up 4.53% at HKD 11.3 [1] - The trading volume reached HKD 80.5031 million [1]

Core Viewpoint - MicroPort Medical's stock rose over 4% following a significant share purchase by JPMorgan, indicating strong investor confidence and potential growth in the company's operations [1] Group 1: Stock Performance - MicroPort Medical (00853) saw its stock increase by 4.53%, reaching HKD 11.3, with a trading volume of HKD 80.5 million [1] Group 2: Shareholder Activity - On November 24, JPMorgan increased its holdings in MicroPort Medical by 89.06 million shares, valued at approximately HKD 930 million [1] - Following this purchase, JPMorgan's total shareholding rose to 276 million shares, increasing its ownership percentage from 9.79% to 14.44% [1] Group 3: Analyst Ratings and Future Outlook - Bank of America reiterated a "Buy" rating for MicroPort Medical, citing attractive risk-reward dynamics [1] - The company has a diversified portfolio of high-value consumables, with the surgical robotics segment expected to contribute 19% of total revenue by 2034 [1] - It is anticipated that the major shareholder, Shanghai United Assets and Equity Exchange, may provide financial and operational support, while the company is addressing liquidity concerns and aims to achieve profitability by the first half of 2026 through cost control and divesting non-core assets [1]

Core Viewpoint - MicroPort Medical (00853) saw a significant stock increase of over 4%, closing at HKD 11.3 with a trading volume of HKD 80.5 million, following news of JPMorgan's substantial share acquisition [1] Group 1: Shareholder Activity - JPMorgan increased its stake in MicroPort Medical by acquiring 89.06 million ordinary shares, valued at approximately HKD 930 million [1] - Post-acquisition, JPMorgan's total shareholding rose to 276 million shares, increasing its ownership percentage from 9.79% to 14.44% [1] Group 2: Analyst Ratings and Future Outlook - Bank of America Securities reiterated a "Buy" rating for MicroPort Medical, citing attractive risk-reward dynamics [1] - The company has a diversified portfolio of high-value consumables, with the surgical robotics segment expected to be a key growth driver, projected to contribute 19% of total revenue by 2034 [1] - It is anticipated that MicroPort Medical's major shareholder, Shanghai United Imaging Healthcare, may provide financial and operational support, while the company is addressing liquidity concerns and aims to achieve profitability by the first half of 2026 through cost control and divesting non-core assets [1]

Core Insights - JPMorgan Chase & Co. increased its stake in MicroPort Scientific Corporation (00853.HK) by acquiring 89.0604 million shares at an average price of HKD 10.4413 per share, totaling approximately HKD 930 million [1] - Following this acquisition, JPMorgan's total holdings in MicroPort rose to 276,377,550 shares, increasing its ownership percentage from 9.79% to 14.44% [1] Company Summary - MicroPort Scientific Corporation is a publicly listed company on the Hong Kong Stock Exchange, identified by the stock code 00853 [2] - The recent transaction indicates a significant investment by JPMorgan, reflecting confidence in MicroPort's future performance and potential growth [1][2]

香港联交所最新数据显示，11月24日，摩根大通增持微创医疗(00853)8906.0433万股，每股作价10.4413 港元，总金额约为9.3亿港元。增持后最新持股数目约为2.76亿股，持股比例为14.44%。 ...

智通财经APP获悉，香港联交所最新数据显示，11月24日，摩根大通增持微创医疗(00853)8906.0433万 股，每股作价10.4413港元，总金额约为9.3亿港元。增持后最新持股数目约为2.76亿股，持股比例为 14.44%。 ...